Can Pharma Keep Up With The Challenges Of Digital Healthcare?
The digital revolution is transforming the world of healthcare, which is awash with new technologies and floods of data. In this thought leadership article written in partnership with CMS, Scrip considers the opportunities and challenges for pharma, in light of progress to date.
You may also be interested in...
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.